Posters & publications
TITLE
DOWNLOAD
RANZCO 2024 presentation: a Phase 1 first-in-human study of VP-001 designed to treat retinitis pigmentosa type 11
ARVO 2024 presentation: a peptide conjugated oligonucleotide for the treatment of retinitis pigmentosa type 11
VP-001 as an interventional therapy for patients with PRPF31 mutation-associated retinal dystrophy
Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
RNA therapeutics in the treatment of retinal disease: delivering the potential
Enhancement of antisense oligomer cell penetration in retinal layers using a modular cell penetrating peptide platform
Modulation of CNOT3 expression using antisense oligomers to treat retinitis pigmentosa type 11
GFP-complementation assay to detect functional CPP and protein delivery into living cells
Functional disruption of a disease modifier gene using antisense oligomers: a potential molecular therapy for PRPF31-associated retinitis pigmentosa type 11
Single stranded fully modified-phosphorothioate oligonucleotides can induce structured nuclear inclusions, alter nuclear protein localisation and disturb the transcriptome in vitro
Exploring microperimetry and autofluorescence endpoints for monitoring disease progression in PRPF31-associated retinopathy
Efficient delivery of antisense oligonucleotides using cell penetrating peptides enables potent, durable exon skipping in mouse and human disease models
β-lactamase tools for establishing cell internalisation and cytosolic delivery of cell penetrating peptides
A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery
Cell penetrating peptides for the delivery of ASOs to the neural retina across rodents and NHPs
PYC-001, a peptide-conjugated phosphorodiamidate morpholino oligomer for the treatment of autosomal dominant optic atrophy
PYC-001, a peptide-conjugated phosophorodiamidate morpholino oligomer for the treatment of autosomal dominant optic atrophy